The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Open accessPublished version of a preprint
Abstract
The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-mediated immunity. To facilitate prospective surveillance for such evolution, we map how convalescent plasma antibodies are impacted by all mutations to the spike's receptor-binding domain (RBD), the main target of plasma neutralizing activity. Binding by polyclonal plasma antibodies is affected by mutations in three main epitopes in the RBD, but longitudinal samples reveal that the impact of these mutations on antibody binding varies substantially both among individuals and within the same individual over time. Despite this inter- and intra-person heterogeneity, the mutations that most reduce antibody binding usually occur at just a few sites in the RBD's receptor-binding motif. The most important site is E484, where neutralization by some plasma is reduced >10-fold by several mutations, including one in the emerging 20H/501Y.V2 and 20J/501Y.V3 SARS-CoV-2 lineages. Going forward, these plasma escape maps can inform surveillance of SARS-CoV-2 evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This variant has substitutions in the spike protein at T95I, G142D, E154K, D614G, P681R, Q1071H, and L452R, E484Q in its RBD region, which may provide this variant reduced resistance to neutralization by post-vaccination sera [47].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“The loss of plasma neutralizing activity against B.1.351could be largely attributed to the E484K substitution (Fig. 3b), which has been shown to attenuate the neutralizing activity of convalescent sera 30 .”
From Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) · cites this paper as [30]
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [11]
In the citing paper
“Continued viral evolution led to the emergence and selection of SARS-CoV-2 variants with enhanced infectivity/transmissibility2,3 4,5 and ability to circumvent drug6 and immune control7,8.”
From Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies (2021) · cites this paper as [8]
In the citing paper
“The E484K mutation, which can mediate antibody escape of B.1.351and P.1 variants, has been recently detected in the B.1.1.7 lineage in the United Kingdom, and thus represents a major potential threat for previously immune populations.”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [24]
In the citing paper
“Mutations in the B.1.351and P.1 strains, including E484K and K417N/T, are of high concern, since they partly compromise neutralization generated by previous infection or vaccination [23][24][25] or may increase inherent viral fitness.”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [24]
In the citing paper
“Mutations at F486 are associated with a reduction in neutralizing activity by class 1 (and some class 2) neutralizing antibodies and by polyclonal sera9–11.”
From Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa (2022) · cites this paper as [10]
In the citing paper
“mutations at this position have been associated with a reduction in neutralization by monoclonal antibodies (particularly class 2 antibodies) and polyclonal sera9–11.”
From Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 14×
“…tend to have the largest effect on plasma antibody binding to the RBD, and our neutralization assays (Figures 5A and 5D Brazil) (Faria et al., 2021; Tegally et al., 2020; Voloch et al., 2020); another mutation at the same site (E484Q) has also been found in a smaller number of human isolates…”
InfluentialDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Self-citationData, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Flagged first, then by citations
Research works printed but not linked: 1
- Kemp, 2020, Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion, medRxiv
Cited by
Sorted by citations
Items 301–400 of 1,006
Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China
Sun, Y., Wang, M., Lin, W., Dong, W., & Xu, J. (2023) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2023.01.002 · Cited by 43
Liu, Y., Wang, Z., Zhuang, X., Zhang, S., Chen, Z., Zou, Y., Sheng, J., Li, T., Tai, W., Yu, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37926-7 · Cited by 43
“Similarly,there was extensive person-to-person variation in how mutations affect plasma antibody binding and neutralization 59 .”
Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220948120 · Cited by 39
Self-citationResende, P. C., Gräf, T., Paixão, A. C. D., Appolinario, L., Lopes, R. S., Mendonça, A. C. D. F., da Rocha, A. S. B., Motta, F. C., Neto, L. G. L., Khouri, R., et al. (2021) · Viruses · doi:10.3390/v13050724 · Cited by 45
Widera, M., Wilhelm, A., Toptan, T., Raffel, J. M., Kowarz, E., Roesmann, F., Grözinger, F., Siemund, A. L., Luciano, V., Külp, M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.701198 · Cited by 41
Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
Mancuso, M., Eikenberry, S. E., & Gumel, A. B. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.08.008 · Cited by 42
“…recent studies have shown that naturally-acquired immunity is less likely to produce an immune response to the existing variants than vaccination (Greaney et al., 2021; Skelly et al., 2021), another future extension of the modeling framework we developed in this study is to include the…”
Evolution of the SARS-CoV-2 genome and emergence of variants of concern
Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41
Tran, T. T., Vaage, E. B., Mehta, A., Chopra, A., Tietze, L., Kolderup, A., Anthi, A. K., König, M. S. S., Nygaard, G. O., Lind, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00586-7 · Cited by 47
Lee, W., Subramanian, A., Mueller, S., Levón, K., Nam, C., & Rafailovich, M. H. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c00068 · Cited by 42
Ma, H., Zhang, X., Zheng, P., Dube, P. H., Zeng, W., Chen, S., Cheng, Q., Yang, Y., Wu, Y., Zhou, J., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00700-3 · Cited by 42
SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
Lee, K. S., Wong, T. Y., Russ, B. P., Horspool, A. M., Miller, O. A., Rader, N. A., Givi, J. P., Winters, M. T., Wong, Z. Y., Cyphert, H. A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273430 · Cited by 42
Bouton, T. C., Lodi, S., Turcinovic, J., Schaeffer, B., Weber, S. E., Quinn, E., Korn, C., Steiner, J., Schechter-Perkins, E. M., Duffy, E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab465 · Cited by 49
A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations
Verghese, M., Jiang, B., Iwai, N., Mar, M., Sahoo, M. K., Yamamoto, F. F., Mfuh, K. O., Miller, J. A., Wang, H., Zehnder, J. L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00741-21 · Cited by 40
Ferrari, M., Mekkaoui, L., Ilca, F. T., Akbar, Z., Bughda, R., Lamb, K., Ward, K., Parekh, F., Karattil, R., Allen, C. G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00685-21 · Cited by 37
Buchy, P., Buisson, Y., Cintra, O. A. L., Dwyer, D. E., Nissen, M. D., de Lejarazu, R. O., & Petersen, E. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.045 · Cited by 46
Wu, W.-L., Chiang, C.-Y., Lai, S.-C., Yu, C.-Y., Huang, Y., Liao, H., Liao, C., Chen, H., & Liu, S. (2022) · JCI Insight · doi:10.1172/jci.insight.157597 · Cited by 41
Cross-Species Tropism and Antigenic Landscapes of Circulating SARS-CoV-2 Variants
Zhang, Y., Wei, M., Wu, Y., Wang, J., Hong, Y., Huang, Y., Yuan, L., Ma, J., Wang, K., Wang, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2022.110558 · Cited by 40
Reutovich, A. A., Srivastava, A. K., Arosio, P., & Bou‐Abdallah, F. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130288 · Cited by 41
Chatterjee, S., Bhattacharya, M., Dhama, K., Lee, S., & Chakraborty, C. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.013 · Cited by 40
Focosi, D., McConnell, S. A., Sullivan, D. J., & Casadevall, A. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100991 · Cited by 39
Sun, R., Qian, M. G., & Zhang, X. (2024) · mAbs · doi:10.1080/19420862.2024.2324836 · Cited by 46
“69 A divergent way to map the pBCEs is to dissemble the pAbs repertoire into mAbs for individual BCE characterization.”
BackgroundSimultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38
Malladi, S. K., Patel, U. R., Rajmani, R. S., Singh, R., Pandey, S., Kumar, S., Khaleeq, S., van Vuren, P. J., Riddell, S., Goldie, S., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00276 · Cited by 38
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2
Liang, Y., Zhang, J., Yuan, R. Y., Wang, M. Y., He, P., Su, J. G., Han, Z. B., Jin, Y. Q., Hou, J. W., Zhang, H., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00383-5 · Cited by 42
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 39
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Alleva, D. G., Delpero, A. R., Scully, M. M., Murikipudi, S., Ragupathy, R., Greaves, E. K., Sathiyaseelan, T., Haworth, J. R., Shah, N. J., Rao, V., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.077 · Cited by 39
Leveraging deep learning to improve vaccine design
Hederman, A. P., & Ackerman, M. E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.002 · Cited by 41
Flores-Alanis, A., Cruz‐Rangel, A., Rodríguez‐Gómez, F., González, J., Torres-Guerrero, C. A., Delgado, G., Cravioto, A., & Morales-Espinosa, R. (2021) · Pathogens · doi:10.3390/pathogens10020184 · Cited by 40
Law, J. L., Logan, M. R., Joyce, M., Landi, A., Hockman, D. J., Crawford, K., Johnson, J., LaChance, G., Saffran, H. A., Shields, J. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.081 · Cited by 41
Self-citationUbah, O. C., Lake, E. W., Gunaratne, G. S., Gallant, J. P., Fernie, M., Robertson, A. J., Marchant, J. S., Bold, T. D., Langlois, R. A., Matchett, W. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27611-y · Cited by 38
Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P., Johnson, C. D., Annapareddy, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.016 · Cited by 39
“The remaining 12 target all four classes of neutralizing RBD epitopes (Barnes et al., 2020; Greaney et al., 2021c).”
Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Grüning, B. A., Shank, S. D., Weaver, S., MacLean, O. A., Orton, R. J., Lemey, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.14.476382 · Cited by 40
Self-citationThe hindrances to perform the COVID-19 vaccination in Brazil
Boschiero, M. N., Palamim, C. V. C., & Marson, F. A. L. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1955607 · Cited by 41
Ye, F., Lin, X., Chen, Z., Yang, F., Lin, S., Yang, J., Chen, H., Sun, H., Wang, L., Wen, A., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00756-4 · Cited by 37
Farrell, A. G., Dadonaite, B., Greaney, A. J., Eguia, R. T., Loes, A. N., Franko, N., Logue, J. K., Carreño, J. M., Abbad, A., Chu, H. Y., et al. (2022) · Viruses · doi:10.3390/v14092061 · Cited by 33
Self-citationCoincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
Ozer, E. A., Simons, L. M., Adewumi, O. M., Fowotade, A. A., Omoruyi, E. C., Adeniji, J. A., Dean, T. J., Zayas, J., Bhimalli, P. P., Ash, M. K., et al. (2021) · doi:10.1101/2021.04.09.21255206 · Cited by 34
The variants of SARS‐CoV‐2 and the challenges of vaccines
Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37
Negi, S. S., Schein, C. H., & Braun, W. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-04950-4 · Cited by 35
The COVID-19 vaccine development: A pandemic paradigm
Carneiro, D. D. C., Sousa, J. D. O., & Monteiro-Cunha, J. P. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198454 · Cited by 37
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 39
Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape
Sun, M., Wu, Z., Zhang, J., Chen, M., Lu, Y. W. W., Yang, C. J., & Song, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101499 · Cited by 36
Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
González-Vázquez, L. D., & Arenas, M. (2023) · Genes · doi:10.3390/genes14020407 · Cited by 44
Antigenic evolution of SARS coronavirus 2
Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36
Using big sequencing data to identify chronic SARS-Coronavirus-2 infections
Harari, S., Miller, D., Fleishon, S., Burstein, D., & Stern, A. (2024) · Nature Communications · doi:10.1038/s41467-024-44803-4 · Cited by 37
Tu, H., Avenarius, M. R., Kubatko, L. S., Hunt, M., Pan, X., Ru, P., Garee, J. P., Thomas, K., Mohler, P. J., Pancholi, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.12.426407 · Cited by 36
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Mlčochová, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T. A., Ferreira, I., Datir, R. P., et al. (2021) · Greater South Information System · doi:10.60692/dy28a-h7650 · Cited by 44
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Nuqui, X., Casalino, L., Zhou, L., Shehata, M., Wang, A., Tse, A. L., Ojha, A. A., Kearns, F. L., Rosenfeld, M. A., Miller, E. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50976-9 · Cited by 33
Liu, Z., Xu, W., Chen, Z., Fu, W., Zhan, W., Gao, Y., Zhou, J., Zhou, Y., Wu, J., Wang, Q., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00871-6 · Cited by 38
“1 variants, are associated with the antibody escape phenotype (Greaney et al., 2021; Madhi et al., 2021; Chen et al., 2021b).”
InfluentialLusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts
Ko, K. K. K., Yingtaweesittikul, H., Tan, T. T., Wijaya, L., Cao, D. Y., Goh, S. S., Rahman, N. B. A., Chan, K. X. L., Tay, H. M., Sim, J. H. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00791-22 · Cited by 37
Characterization of the SARS-CoV-2 B.1.621 (Mu) variant
Halfmann, P., Kuroda, M., Armbrust, T., Theiler, J. P., Balaram, A., Moreno, G. K., Accola, M. A., Iwatsuki‐Horimoto, K., Valdez, R., Stoneman, E. K., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm4908 · Cited by 35
“In addition, the E484K mutation has been shown to affect antibody resistance to convalescent and vaccine serum samples ( 9 , 10 ).”
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · PubMed · doi:10.34944/dspace/7022 · Cited by 49
Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic
Yavarian, J., Nejati, A., Salimi, V., Shafiei-Jandaghi, N.-Z., Sadeghi, K., Abedi, A., Sharifi‐Zarchi, A., Gouya, M. M., & Mokhtari‐Azad, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267847 · Cited by 35
Adaptive Evolution of the Spike Protein in Coronaviruses
Tang, X., Qian, Z., Lu, X., & Lü, J. (2023) · Molecular Biology and Evolution · doi:10.1093/molbev/msad089 · Cited by 36
“…have become increasingly important driving forces underlying SARS-CoV-2 evolution (Starr et al. 2020; Andreano et al. 2021; Cao et al. 2021, 2023; Greaney et al. 2021a, 2021b; Hu et al. 2021; Planas et al. 2021; Cao et al. 2022a, 2022b; Tan et al. 2022; Tegally et al. 2022).”
BackgroundUmair, M., Ikram, A., Salman, M., Haider, S. A., Badar, N., Rehman, Z., Ammar, M., Rana, M. S., & Ali, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27429 · Cited by 44
Dicken, S. J., Murray, M. J., Thorne, L., Reuschl, A., Forrest, C., Ganeshalingham, M., Muir, L., Kalemera, M. D., Palor, M., McCoy, L. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436468 · Cited by 30
Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro
Pucci, F., & Rooman, M. J. (2021) · Viruses · doi:10.3390/v13050935 · Cited by 35
A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays
Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 34
Lam, J. H., Shivhare, D., Chia, T. W., Chew, S. L., Sinsinbar, G., Aw, T. Y., Wong, S., Venkataraman, S., Lim, F. W. I., Vandepapelière, P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06350 · Cited by 33
Zhao, Y., Ni, W., Liang, S., Dong, L., Xiang, M., Cai, Z., Niu, D., Zhang, Q., Wang, D., Zheng, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3332 · Cited by 34
COVID-19: Epidemiologie und Mutationen
Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 33
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 34
Meng, Z., Guo, S., Zhou, Y., Li, M., Wang, M., & Ying, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00731-z · Cited by 35
Lamarca, A. P., de Almeida, L. G. P., Francisco, R. D. S., Agnez‐Lima, L. F., Scortecci, K. C., Perez, V. P., Brustolini, O. J. B., Sousa, E. S. S., Secco, D., Santos, Â., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009835 · Cited by 35
“from both polyclonal and monoclonal antibodies [60,61]; E484K has been associated with escape from both vaccines and previous infections [2,10,62–64]; and N501Y leads to increased binding specificity to the receptor and is associated with high transmissibility while also escaping immune response [65,66].”
BackgroundThe Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34
Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein
Staufer, O., Gupta, K., Bücher, J. E. H., Köhler, F., Sigl, C., Singh, G., Vasileiou, K., Relimpio, A. Y., Macher, M., Fabritz, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28446-x · Cited by 36
Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond
Faist, A., Janowski, J., Kumar, S., Hinse, S., Çalışkan, D. M., Lange, J., Ludwig, S., & Brunotte, L. (2022) · Cells · doi:10.3390/cells11142198 · Cited by 31
Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data
Lee, B., Quadeer, A. A., Sohail, M. S., Finney, E., Ahmed, S. F., McKay, M. R., & Barton, J. P. (2025) · Nature Communications · doi:10.1038/s41467-024-55593-0 · Cited by 32
Saliu, T. P., Umar, H. I., Ogunsile, O. J., Okpara, M. O., Yanaka, N., & Elekofehinti, O. O. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00273-5 · Cited by 32
Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer
Wright, D. W., Harvey, W. T., Hughes, J., Cox, M., Peacock, T. P., Colquhoun, R., Jackson, B., Orton, R. J., Nielsen, M., Hsu, S. N., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac023 · Cited by 31
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30
How will emerging SARS-CoV-2 variants impact herd immunity?
Lippi, G., & Henry, B. M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-893 · Cited by 33
Röltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
Maher, M. C., Bartha, I., Weaver, S., di Iulio, J., Ferri, E., Soriaga, L. B., Lempp, F. A., Hie, B., Bryson, B. D., Berger, B., et al. (2021) · DSpace@MIT (Massachusetts Institute of Technology) · doi:10.34944/dspace/6982 · Cited by 31
Kuzmina, A., Wattad, S., Khalaila, Y., Ottolenghi, A., Rosental, B., Engel, S., Rosenberg, E., & Taube, R. (2021) · iScience · doi:10.1016/j.isci.2021.103467 · Cited by 33
Cotten, M. L., & Phan, M. V. T. (2023) · iScience · doi:10.1016/j.isci.2023.106230 · Cited by 31
Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 30
“E484K replacement alters the immunologic pro fi le of SARS-CoV-2, 38,39,53 e 55 and Greaney et al 56 reported that E484Q reduced viral neutralization for some plasma samples.”
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31
“Importantly, compared with the D614 and D614G lineages, most of these variants, especially those harboring E484K/Q mutants, confer elevated resistance to neutralization from convalescent COVID-19 sera as well as many therapeutic monoclonal antibodies (Garcia-Beltran et al., 2021; Greaney et al., 2021; Hoffmann et al.,…”
Macioła, A. K., Raja, M. L., Pacenti, M., Salata, C., Silvestro, G. D., Rosato, A., & Pasqual, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830710 · Cited by 31
Antibody escape and global spread of SARS-CoV-2 lineage A.27
Kaleta, T., Kern, L., Hong, S. L., Hölzer, M., Kochs, G., Beer, J., Schnepf, D., Schwemmle, M., Bollen, N., Kolb, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28766-y · Cited by 33
Nkosi, T., Chasara, C., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T. L., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., et al. (2022) · eLife · doi:10.7554/elife.78374 · Cited by 31
Cheng, Z., Elmes, M. J., Kirkup, S. E., Abayasekara, D. R. E., & Wathes, D. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1820249 · Cited by 31
de Oliveira, M. H. S., Lippi, G., & Henry, B. M. (2021) · medRxiv · doi:10.1101/2021.03.24.21254046 · Cited by 30
“The E484K has been reported to be associated with humoral immune escape, as observed in reports of decreased neutralization efficacy of convalescent plasma and sera from vaccinated individuals, as well as reports of re-infection.(5) In particular, the P.”
BackgroundWaning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38
Garrett, M. E., Galloway, J. G., Wolf, C., Logue, J. K., Franko, N., Chu, H. Y., Matsen, F. A., IV, & Overbaugh, J. (2022) · eLife · doi:10.7554/elife.73490 · Cited by 32
Self-citationTaus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31
Karges, J., Giardini, M. A., Blacque, O., Woodworth, B., Siqueira-Neto, J. L., & Cohen, S. M. (2022) · Chemical Science · doi:10.1039/d2sc05473f · Cited by 29
Graninger, M., Jani, C. M., Reuberger, E., Prüger, K., Gaspar, P., Springer, D. N., Borsodi, C., Weidner, L., Rabady, S., Puchhammer‐Stöckl, E., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02314-22 · Cited by 29
Wang, Y., Yan, A., Song, D., Duan, M., Dong, C., Chen, J., Jiang, Z., Gao, Y., Rao, M., Feng, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45050-3 · Cited by 29
Gand, M., Vanneste, K., Thomas, I., Gucht, S. V., Capron, A., Herman, P., Roosens, N. H. C., & Keersmaecker, S. C. J. D. (2021) · Genes · doi:10.3390/genes12040565 · Cited by 29
Role of SARS-CoV-2 and ACE2 variations in COVID-19
Antony, P., & Vijayan, R. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.04.006 · Cited by 32
Tsai, K., Lee, Y.-C., & Tseng, T.-S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698365 · Cited by 32
Saville, J. W., Berezuk, A., Srivastava, S. S., & Subramaniam, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01062 · Cited by 32
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Khan, R. U., Almakdi, S., Alshehri, M. S., Kumar, R., Ali, I., Hussain, S. M., Haq, A. U., Khan, I. U., Ullah, A., & Uddin, M. I. (2022) · Diagnostics · doi:10.3390/diagnostics12102539 · Cited by 29
López-Morales, J., Vanella, R., Appelt, E. A., Whillock, S., Paulk, A. M., Shusta, E. V., Hackel, B. J., Liu, C. C., & Nash, M. A. (2023) · Small Science · doi:10.1002/smsc.202300095 · Cited by 28
SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines
Li, X., Mi, Z., Liu, Z., & Rong, P. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1334152 · Cited by 34
Williams, G. H., Llewelyn, A., Brandão, R. A. R., Chowdhary, K., Hardisty, K.-M., & Loddo, M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101021 · Cited by 26
Fernandez, R. A. T., Quimque, M. T. J., Notarte, K. I., Manzano, J. A., Pilapil, D. Y. H., de Leon, V. N., Jose, J. J. P. S., Villalobos, O. A., Muralidharan, N. H., Gromiha, M. M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1969281 · Cited by 29
Metadata
- Authors
- Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D.
- Affiliations
- University of Washington (US)
- Howard Hughes Medical Institute (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 29
- Issue
- 3
- Pages
- 463-476.e6
- ISSN
- 1931-3128 (ISSN-L)
- PMC
- PMC7869748
- OpenAlex
- W3127852352
- Cited by
- 1,178
- References
- 88
- Citations by year
- 2026: 43 · 2025: 64 · 2024: 79 · 2023: 158 · 2022: 361 · 2021: 459
- FWCI
- 83.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 374 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell Host & Microbe (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gates Foundation (INV-004949)
- Howard Hughes Medical Institute
- NIAID (T32AI083203, R01AI141707, F30AI149928, R01AI127893)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Office of Research Infrastructure Programs, National Institutes of Health (S10OD028685)
- National Institutes of Health
- Vanderbilt University
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, spike protein receptor-binding domain, antibody escape mutations, neutralizing antibodies, E484K mutation, antibody epitopes, convalescent plasma, humoral immunity
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Monoclonal, Antibodies, Viral, Binding Sites, Cell Line, Female, Humans, Male, Middle Aged, Mutation, Prospective Studies, Protein Binding, Receptors, Virus, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
